Exit
In order to receive credit for this activity, you must read the front matter, view the activity, achieve a passing of at least 100% on this post-survey, as well as complete the linked evaluation and application for credit form. Certificates of credit will be emailed to participants who have successfully met these requirements. 

There is no fee to participate in this activity.

Question Title

* 1. What are your credentials? 

Question Title

* 2. What is your community of practice?

Question Title

* 3. Which of the following therapies has demonstrated the longest median progression-free survival in phase 1 studies of patients with relapsed/refractory multiple myeloma?

Question Title

* 4. Enrollment of patients with which of the following characteristics is a key difference in the study populations presented in the MonumenTAL-1 (talquetamab) study compared with the MagnetisMM-3, MajesTEC-1, KarMMa-1 or CARTITUDE-1 studies? 

Question Title

* 5. An organizational task force is developing monitoring plans for patients receiving bispecific antibodies for relapsed/refractory multiple myeloma. Monitoring for which of the following adverse effects should be included in monitoring plans for talquetamab but not for elranatamab or teclistamab? 

Question Title

* 6. A 68-year-old male was referred for management of relapsed/refractory multiple myeloma after 7 prior therapies including 2 proteasome inhibitors, 2 immunomodulatory agents, and 2 anti-CD38 monoclonal antibodies. After reviewing treatment options with him, he asks which of the following severe (grade 3 or higher) adverse effects is more likely to occur if he chooses a BCMA-directed bispecific antibody rather than a BCMA-directed CAR-T? Which of the following is the best response? 

Question Title

* 7. A 63-year-old female diagnosed with IgG multiple myeloma with deletion 17p presents for a treatment consult. She received 5 prior therapies including 2 proteasome inhibitors, 2 immunomodulatory agents, and 2 anti-CD38 monoclonal antibodies. She is the caregiver for her spouse with advanced Alzheimer’s disease. They live 200 miles from a cellular therapy center. She wishes to receive treatment close to home. Which therapy is best for her at this time? 

EVALUATION FORM

Question Title

* 8. Upon completion of this activity, I am able to:

  Strongly agree Agree Disagree Strongly disagree
DIFFERENTIATE pivotal trial results of current and emerging BCMA-directed therapies for RRMM
TRANSLATE strategies to monitor and minimize the negative impact of treatment-related toxicities for BCMA-directed therapies in RRMM
DETERMINE appropriate therapy based on patient characteristics, efficacy and safety data, risk assessment, and treatment history for patients with RRMM

Question Title

* 9. Please indicate the extent of your agreement with the following statements:

  Strongly agree Agree Disagree Strongly disagree
The faculty for this activity were effective
The educational resources provided to me at the educational activity are useful to my practice.

Question Title

* 10. Overall, was this activity fair, balanced and free from commercial bias?

Question Title

* 11. If no, please explain:

Question Title

* 12. Of the patients you will see in the next month, about how many will benefit from the information you learned today?

Question Title

* 13. Based on what I learned today, I will improve my practice by incorporating the following (check all that apply):

Question Title

* 14. Based on your experience, which of the following are the primary barriers to implementing changes in practice (check all that apply):

Question Title

* 15. For purposes of certification, please complete the following information. *Please note that we will not forward or sell your contact information.*

Question Title

* 16. I certify that I have participated in the continuing education activity entitled, "Expert Consult #1: Selecting BCMA- and GPRC5D-Directed Therapies in Multiple Myeloma" and claim 0.75 AMA PRA Category 1 CreditTM.

Thank you for participating in our activity and completing the necessary paperwork. Your certificate will be emailed to you using the email address provided above. Please allow 4 weeks to receive your certificate. 

For information about the certification of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.
( Privacy & Cookie Notice

T